Drugs / KB004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03374943 | Dec 2017 → Jan 2021 | glioblastoma | Olivia Newton-John Cancer Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01211691 | Sep 2010 → Jul 2016 | myelodysplastic syndrome, myelofibrosis | Humanigen, Inc. | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01211691 ↗ |
| Modality | Monoclonal antibody | “anti-EphA3 monoclonal antibody KB004” NCT01211691 ↗ |
| Route | Intravenous | “KB004 was administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle.” PMID 27736729 ↗ Sep 2016 |
| Target | EPHA3 | “anti-EphA3 monoclonal antibody KB004” NCT01211691 ↗ |